BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$88.59 USD
-1.48 (-1.64%)
Updated Apr 19, 2024 03:22 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMRN 88.59 -1.48(-1.64%)
Will BMRN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Other News for BMRN
World Hemophilia Day 2024"Equitable access for all: recognizing all bleeding disorders"
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Sales Outlook and Optimized Market Expectations
BioMarin participates in a conference call with JPMorgan.
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Regeneron (REGN)
Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...